相关实验视频

Updated: Jul 5, 2025

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

预防性免疫球蛋白治疗儿科 kongenital myotonic dystrophy 的疾病

Yoji Uejima¹, Satoshi Sato¹

¹Division of Infectious Diseases and Immunology, Saitama Children's Medical Center, Saitama, Japan.

Immunological medicine

|January 25, 2024

概括

具有免疫球蛋白G (IgG) 低水平的先天性肌痛性缩症 (CMD) 患者可以用免疫球蛋白替代疗法治疗. 这一首例儿科病例表明,高剂量的IVIG或SCIG有效地预防了CMD儿童的感染.

科学领域:

遗传学和分子生物学
免疫学免疫学免疫学
儿科医学儿科医学

背景情况:

kongenital myotonic dystrophy (CMD) 是一种自体主导的遗传性疾病.
患有CMD的患者经常出现低血 (低IgG水平).
免疫球蛋白替代疗法已为成年人确立,但未在儿科CMD病例中报告.

研究的目的:

报告第一个患有先天性肌肉变症的儿科病例,同时患有低血糖球蛋白血症.
评估免疫球蛋白替代疗法在预防儿童CMD患者感染方面的疗效.
为了确定在这个人群中免疫球蛋白治疗的最佳剂量和施用途径.

主要方法:

一个1岁的女性患有CMD,早产和死性肠球炎,呈现出重复重复的严重细菌感染.
最初使用静脉注射免疫球蛋白 (IVIG) 剂量为600 mg/kg/月的治疗不足.
剂量升级至2g/kg/月IVIG,随后转换为皮下免疫球蛋白 (SCIG),以维持治疗水平.

主要成果:

增加IVIG剂量和随后的SCIG治疗实现并维持了一年内血清IgG水平在700 mg/dL以上的最低水平.
患者经历了对严重细菌感染的敏感性显著降低.
基因检测排除了常见的可变免疫缺陷和其他原发性免疫缺陷.

结论:

较高剂量的免疫球蛋白替代疗法 (IVIG或SCIG) 有效地治疗儿科CMD患者的低血糖球蛋白血症.
这种方法在报告的病例中成功预防了严重的感染.
需要进行进一步的研究,以阐明CMD中低甘球蛋白血的机制,并优化治疗策略.

关键词:

这种情况是Hypogammaglobulinemia.静脉内注射的免疫球蛋白是什么新生儿fc受体新生儿fc受体儿科的先天性肌肉性缩症.皮下注射的免疫球蛋白是可以使用的.

更多相关视频

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Published on: July 15, 2014

相关概念视频

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Satellite Stem Cells and Muscular Dystrophy

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...